SEGMENT AND ENTERPRISE-WIDE INFORMATION

6 Months Ended

Sep. 30, 2017

Segment Reporting [Abstract]

SEGMENT AND ENTERPRISE-WIDE INFORMATION

SEGMENT AND ENTERPRISE-WIDE INFORMATION

We determine our reportable segments by first identifying our operating segments, and then by assessing whether any components of these segments constitute a business for which discrete financial information is available and where segment management regularly reviews the operating results of that component. Our operating segments are based primarily on geography. North America Plasma is a separate operating segment with dedicated segment management due the size and scale of the Plasma business unit. We aggregate components within an operating segment that have similar economic characteristics.

The Company’s reportable segments are as follows:

• Japan

• EMEA

• North America Plasma

• All Other

The Company has aggregated the Americas Blood Center and Hospital and Asia - Pacific operating segments into the All Other reportable segment based upon their similar operational and economic characteristics, including similarity of operating margin.

Management measures and evaluates the operating segments based on operating income. Management excludes certain corporate expenses from segment operating income. In addition, certain amounts that management considers to be non-recurring or non-operational are excluded from segment operating income because management evaluates the operating results of the segments excluding such items. These items include restructuring and turnaround costs, deal amortization, and asset impairments. Although these amounts are excluded from segment operating income, as applicable, they are included in the reconciliations that follow. Management measures and evaluates the Company's net revenues and operating income using internally derived standard currency exchange rates that remain constant from year to year; therefore, segment information is presented on this basis.

During the first quarter of fiscal 2018, management changed the cost reporting structure such that a portion of corporate expenses were reclassified into the operating segments. Accordingly, the prior year numbers have been updated to reflect this reclassification.

Selected information by business segment is presented below:

	Three Months Ended						Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016			September 30, 2017			October 1, 2016
Net revenues
Japan	$	17,164		$	18,991		$	32,396		$	33,557
EMEA	43,786			45,933			86,794			91,674
North America Plasma	85,051			78,292			162,587			151,767
All Other	80,193			78,411			158,367			156,431
Net revenues before foreign exchange impact	226,194			221,627			440,144			433,429
Effect of exchange rates	(817		)	(1,374		)	(3,816		)	(3,220		)
Net revenues	$	225,377		$	220,253		$	436,328		$	430,209

	Three Months Ended						Six Months Ended
(In thousands)	September 30, 2017			October 1, 2016			September 30, 2017			October 1, 2016
Segment operating income
Japan	$	7,877		$	9,017		$	14,615		$	15,173
EMEA	8,239			8,577			16,810			16,853
North America Plasma	32,184			26,151			56,286			51,318
All Other	30,052			30,946			57,738			58,116
Segment operating income	78,352			74,691			145,449			141,460
Corporate operating expenses	(42,905		)	(41,921		)	(82,216		)	(88,059		)
Effect of exchange rates	1,102			667			(1,099		)	(639		)
Restructuring and turnaround costs	(5,787		)	(1,637		)	(8,270		)	(20,453		)
Deal amortization	(6,504		)	(7,006		)	(12,995		)	(14,081		)
Asset impairments	—			—			—			(1,315		)
Operating income	$	24,258		$	24,794		$	40,869		$	16,913

Our products are organized into four categories for purposes of evaluating their growth potential: Plasma, Blood Center, Cell Processing and Hemostasis Management. Management reviews revenue trends based on these business units; however, no other financial information is currently available on this basis.

Net revenues by business unit are as follows:

	Three Months Ended				Six Months Ended
(In thousands)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
Plasma	$	109,771	$	103,564	$	211,278	$	201,213
Blood Center	71,710		74,270		137,275		145,213
Cell Processing	25,764		25,955		52,100		52,031
Hemostasis Management	18,132		16,464		35,675		31,752
Net revenues	$	225,377	$	220,253	$	436,328	$	430,209

Net revenues generated in our principle operating regions on a reported basis are as follows:

	Three Months Ended				Six Months Ended
(In thousands)	September 30, 2017		October 1, 2016		September 30, 2017		October 1, 2016
United States	$	138,779	$	130,843	$	269,831	$	256,543
Japan	16,732		21,666		31,648		36,630
Europe	39,133		37,606		76,355		77,973
Asia	28,831		28,384		54,771		55,376
Other	1,902		1,754		3,723		3,687
Net revenues	$	225,377	$	220,253	$	436,328	$	430,209